184 related articles for article (PubMed ID: 26512827)
1. Late gadolinium enhancement image masquerading as hypertrophic cardiomyopathy in Fabry disease receiving enzyme replacement therapy.
Yano T; Oshima H; Miki T; Tanaka M; Muranaka A; Osanami A; Takahashi F; Miura T
Int J Cardiol; 2016 Jan; 203():136-7. PubMed ID: 26512827
[No Abstract] [Full Text] [Related]
2. Merging strain-echo measurements with late gadolinium enhancement at cardiac MRI: An upcoming chance for advanced functional assessment of fibrosis in hypertrophic cardiomyopathy?
de Gregorio C; Di Bella G
Int J Cardiol; 2016 Jan; 203():632-4. PubMed ID: 26590884
[No Abstract] [Full Text] [Related]
3. Significance of Late Gadolinium Enhancement at Right Ventricular Attachment to Ventricular Septum in Patients With Hypertrophic Cardiomyopathy.
Chan RH; Maron BJ; Olivotto I; Assenza GE; Haas TS; Lesser JR; Gruner C; Crean AM; Rakowski H; Rowin E; Udelson J; Lombardi M; Tomberli B; Spirito P; Formisano F; Marra MP; Biagini E; Autore C; Manning WJ; Appelbaum E; Roberts WC; Basso C; Maron MS
Am J Cardiol; 2015 Aug; 116(3):436-41. PubMed ID: 26026863
[TBL] [Abstract][Full Text] [Related]
4. Cardiac Magnetic Resonance Late Gadolinium Enhancement Imaging in Arrhythmic Risk Stratification.
Nucifora G; Selvanayagam JB
Heart Lung Circ; 2020 Sep; 29(9):1268-1269. PubMed ID: 32718901
[No Abstract] [Full Text] [Related]
5. Comparison of different quantification methods of late gadolinium enhancement in patients with hypertrophic cardiomyopathy.
Spiewak M; Malek LA; Misko J; Chojnowska L; Milosz B; Klopotowski M; Petryka J; Dabrowski M; Kepka C; Ruzyllo W
Eur J Radiol; 2010 Jun; 74(3):e149-53. PubMed ID: 19523780
[TBL] [Abstract][Full Text] [Related]
6. Usefulness of high-sensitivity cardiac troponin T and brain natriuretic peptide as biomarkers of myocardial fibrosis in patients with hypertrophic cardiomyopathy.
Kawasaki T; Sakai C; Harimoto K; Yamano M; Miki S; Kamitani T
Am J Cardiol; 2013 Sep; 112(6):867-72. PubMed ID: 23746480
[TBL] [Abstract][Full Text] [Related]
7. Fabry disease in patients with hypertrophic cardiomyopathy (HCM).
Beer G; Reinecke P; Gabbert HE; Hort W; Kuhn H
Z Kardiol; 2002 Dec; 91(12):992-1002. PubMed ID: 12490989
[TBL] [Abstract][Full Text] [Related]
8. Letter regarding Morsbach et al. "Quantitative comparison of 2D and 3D late gadolinium enhancement MR imaging in patients with Fabry disease and hypertrophic cardiomyopathy".
Ma H; Wang Y; Wang Y; Shi L; Zhang J; Wen Z; Chen L; Wang Z; Shi Y; Sun C; Pan Y; Liu J; Xie H; Yang J
Int J Cardiol; 2018 Apr; 256():35. PubMed ID: 29395363
[No Abstract] [Full Text] [Related]
9. LGE and the risk of sudden death in HCM.
Alla VM; Koneru S; Hunter C; Mooss A
JACC Cardiovasc Imaging; 2012 Jul; 5(7):761-2; author reply 762-3. PubMed ID: 22789948
[No Abstract] [Full Text] [Related]
10. Histologic and electron microscopy findings in myocardium of treated Fabry disease.
Owens CL; Russell SD; Halushka MK
Hum Pathol; 2006 Jun; 37(6):764-8. PubMed ID: 16733219
[TBL] [Abstract][Full Text] [Related]
11. Fabry disease in cardiology practice: Literature review and expert point of view.
Hagège A; Réant P; Habib G; Damy T; Barone-Rochette G; Soulat G; Donal E; Germain DP
Arch Cardiovasc Dis; 2019 Apr; 112(4):278-287. PubMed ID: 30826269
[TBL] [Abstract][Full Text] [Related]
12. Prognostic Significance of Cardiac Magnetic Resonance Imaging Late Gadolinium Enhancement in Fabry Disease.
Hanneman K; Karur GR; Wasim S; Morel CF; Iwanochko RM
Circulation; 2018 Nov; 138(22):2579-2581. PubMed ID: 30571357
[No Abstract] [Full Text] [Related]
13. Severe Late-Onset Fabry Cardiomyopathy Unmasked by a Multimodality Imaging Approach.
Visoiu IS; Ciobanu AO; Nicula AI; Iascone M; Jurcut R; Vinereanu D; Rimbas RC
Circ Cardiovasc Imaging; 2019 Nov; 12(11):e009709. PubMed ID: 31630529
[No Abstract] [Full Text] [Related]
14. Myocardial lipid content in Fabry disease: a combined
Petritsch B; Köstler H; Weng AM; Horn M; Gassenmaier T; Kunz AS; Weidemann F; Wanner C; Bley TA; Beer M
BMC Cardiovasc Disord; 2016 Oct; 16(1):205. PubMed ID: 27793097
[TBL] [Abstract][Full Text] [Related]
15. Ventricular Hinge Point Fibrosis as a Pathological Marker of Hypertrophic Cardiomyopathy in the Absence of Significant Left Ventricular Hypertrophy?
Ding WY; Cooper RM; Hasleton J; McKay V; Modi S
Can J Cardiol; 2016 Dec; 32(12):1577.e13-1577.e14. PubMed ID: 27177834
[TBL] [Abstract][Full Text] [Related]
16. Original report. Late myocardial enhancement in hypertrophic cardiomyopathy with contrast-enhanced MR imaging.
Bogaert J; Goldstein M; Tannouri F; Golzarian J; Dymarkowski S
AJR Am J Roentgenol; 2003 Apr; 180(4):981-5. PubMed ID: 12646440
[TBL] [Abstract][Full Text] [Related]
17. Delayed contrast enhancement CMR imaging in apical hypertrophic cardiomyopathy.
Jassal DS; Chaithiraphan V; Neilan TG; Cury RC
Int J Cardiol; 2006 Nov; 113(2):e56-7. PubMed ID: 16769137
[No Abstract] [Full Text] [Related]
18. [Clinical significance of late gadolinium enhancement on cardiovascular magnetic resonance in patients with hypertrophic cardiomyopathy].
Dumont CA; Monserrat L; Soler R; Rodríguez E; Fernández X; Peteiro J; Bouzas B; Piñón P; Castro-Beiras A
Rev Esp Cardiol; 2007 Jan; 60(1):15-23. PubMed ID: 17288951
[TBL] [Abstract][Full Text] [Related]
19. Distribution of late gadolinium enhancement in end-stage hypertrophic cardiomyopathy and dilated cardiomyopathy: differential diagnosis and prediction of cardiac outcome.
Machii M; Satoh H; Shiraki K; Saotome M; Urushida T; Katoh H; Takehara Y; Sakahara H; Ohtani H; Wakabayashi Y; Ukigai H; Tawarahara K; Hayashi H
Magn Reson Imaging; 2014 Feb; 32(2):118-24. PubMed ID: 24315973
[TBL] [Abstract][Full Text] [Related]
20. Late gadolinium enhancement cardiac magnetic resonance imaging in prognostic assessment of hypertrophic cardiomyopathy.
Bouabdallaoui N; Ennezat PV; Durand E; Puymirat E; Macron L
Eur Heart J Cardiovasc Imaging; 2013 Oct; 14(10):1024. PubMed ID: 23644935
[No Abstract] [Full Text] [Related]
[Next] [New Search]
